Genitourinary Cancer
From the Journals
Novel agent varlilumab shows activity in RCC
A total of eight patients achieved stable disease in the phase I study, including four with RCC.
News
Durvalumab approved for advanced urothelial carcinoma
The Food and Drug Administration has granted accelerated approval to the checkpoint inhibitor durvalumab for patients with locally advanced or...
Community Translations
Lenvatinib expands its reach into renal cell carcinoma
The US Food and Drug Administration (FDA) expanded the approval of the multitargeted tyrosine kinase inhibitor lenvatinib to a second indication...
Case Reports
Paraneoplastic leukemoid reaction – poor prognostic marker in urothelial bladder carcinoma
From the Journals
Ultrasound, cystoscopy combo tops CT for asymptomatic microscopic hematuria
Combining renal ultrasound and bladder cystoscopy is the most cost-effective approach for the initial evaluation of asymptomatic microscopic...
From the Journals
Metformin linked with better survival in RCC patients with diabetes
A meta-analysis of eight studies including 254,329 patients found better survival with metformin use.
New Therapies
Liquid gold: blood-based biopsies make headway
Feature
Unavoidable, random DNA replication errors are the most common cancer drivers
Up to two-thirds of the mutations that drive human cancers may be due to DNA replication errors in normally dividing stem cells, not by inherited...
Original Report
Point of prostate cancer diagnosis experiences and needs of black men: the Florida CaPCaS study
From the Journals
No benefit from adjuvant sunitinib or sorafenib for clear cell renal cancer
Secondary analysis of data from the ASSURE trial does not support an adjuvant strategy.
Conference Coverage
Outcomes of neoadjuvant therapy vary by subtype in bladder cancer
Clinical outcomes for neoadjuvant chemotherapy vary by molecular subtype in muscle-invasive bladder cancer.